Infections à Clostridioides difficile : mise au point et repères thérapeutiques (notice n° 648178)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05461cam a2200313 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121183814.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Berrut, Gilles |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Infections à Clostridioides difficile : mise au point et repères thérapeutiques |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 56 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Clostridioides difficile infection (CDI) represents a significant challenge due to its increasing incidence, severity, and treatment difficulty. Effective management requires a multifactorial approach that includes preventive strategies, prudent antibiotic use, and adapted therapeutic options. Ongoing research and innovation offer promising prospects for improving ICD management, making vigilance and informed practices essential among healthcare professionals. Two main complications of ICD are pseudomembranous colitis (PMC) and toxic megacolon. PMC involves severe colonic inflammation due to C. difficile toxins, leading to pseudomembrane formation. Diagnosis relies on clinical criteria, microbiological tests, and endoscopy. Toxic Megacolon is characterized by severe colonic dilation and systemic toxicity, requiring immediate medical intervention. ICD diagnosis combines clinical signs and microbiological tests. These tests include toxin tests, GDH antigen detection, PCR for toxin genes, and stool culture. Imaging techniques assess colonic inflammation and complications. Combined diagnostic criteria from the American Gastroenterological Association (AGA) and European guidelines emphasize integrating clinical and laboratory findings for accurate diagnosis. ICD treatment involves stopping the implicated antibiotics and starting specific antimicrobial therapy. Common treatments include mainly fidaxomicin and oral vancomycin.Fecal microbiota transplantation (TMF) is recommended for recurrent cases unresponsive to standard treatments. Bezlotoxumab, an antibody targeting C. difficile toxin B, is used to prevent recurrence in high-risk adults.ICD poses a major challenge due to its increasing incidence, severity, and difficulty in treatment. A multifactorial approach involving rigorous preventive strategies, prudent antibiotic management, and adapted therapeutic options is essential for controlling the infection. Ongoing research and innovations in treatment offer promising prospects for improving patient management. Healthcare professionals must remain vigilant and informed to ensure effective practices in combating this infection and utilizing available resources optimally. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les infections à Clostridioides difficile (ICD) représentent un défi majeur en raison de leur incidence croissante, de leur gravité et de la difficulté de leur traitement. Une gestion efficace nécessite une approche multifactorielle incluant des stratégies préventives, une utilisation appropriée et raisonnée des antibiotiques et des options thérapeutiques adaptées. La recherche continue et l’innovation offrent des perspectives prometteuses pour améliorer la gestion des ICD, rendant la formation, la vigilance et les bonnes pratiques essentielles pour les professionnels de la santé.Les principales complications des ICD sont la colite pseudomembraneuse (CPM), le mégacôlon toxique et aussi les déshydratations avec insuffisance rénale aiguë et perte fonctionnelle. La CPM implique une inflammation sévère du côlon due aux toxines de C. difficile, conduisant à la formation de pseudomembranes. Le mégacôlon toxique se caractérise par une dilatation sévère du côlon et une toxicité systémique, nécessitant une intervention médicale immédiate.Le diagnostic des ICD combine les signes cliniques et les tests microbiologiques, incluant les tests de détection de toxines, la détection de l’antigène GDH, la PCR pour les gènes de toxines et la culture de selles.Le traitement consiste à arrêter les antibiotiques en cause dans la mesure du possible et à commencer une thérapie antimicrobienne spécifique qui incluent essentiellement la fidaxomicine et la vancomycine orale. La transplantation de microbiote fécal (TMF) est recommandée pour les cas récurrents non réactifs aux traitements standards. Le bezlotoxumab, un anticorps ciblant la toxine B de C. difficile, est utilisé pour prévenir les récidives chez les adultes à haut risque.Une approche multifactorielle est essentielle pour contrôler les ICD. La recherche continue et l’innovation dans les traitements offrent des perspectives prometteuses pour améliorer la prise en charge des patients. Les professionnels de santé doivent rester vigilants et informés pour assurer des pratiques efficaces contre cette infection et optimiser l’utilisation des ressources disponibles. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement revu |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | entérocolite |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clostridioides difficile |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | sujet âgé |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | elderly patient |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | enterocolitis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | treatment review |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clostridioides difficile |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Roubaud Baudron, Claire |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Paccalin, Marc |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | De Wazières, Benoît |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gavazzi, Gaétan |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Gériatrie et Psychologie Neuropsychiatrie du Vieillissement | 22 | 3 | 2024-10-31 | p. 316-324 | 2115-8789 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-geriatrie-et-psychologie-neuropsychiatrie-du-vieillissement-2024-3-page-316?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-geriatrie-et-psychologie-neuropsychiatrie-du-vieillissement-2024-3-page-316?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux